After many years without love, RA-ILD therapy seems like it's on the move. MUC5B aside, we've seen abstracts at #EULAR2021 about: - tofacitinib (OP0125) - abatacept (POS0513) - rituximab (POS0645) - nintedanib (below) I discuss it a bit for @RheumNow: https://t.co/nk87kfjacb https://t.co/EjNbA2oLWs